title: Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease.
authors.forename: Junji
authors.initials: J
authors.lastname: Umeno
authors.forename: Takayuki
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Jo
authors.forename: Miki
authors.initials: M
authors.lastname: Ichikawa
authors.forename: Kazunori
authors.initials: K
authors.lastname: Urabe
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Iida
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003424:Crohn Disease / Q000150:complications* / Q000175:diagnosis; D018450:Disease Progression; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D000069285:Infliximab; D011565:Psoriasis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab